Advancing Cardiomyocyte Maturation: Current Strategies and Promising Conductive Polymer‐Based Approaches

Abstract

Cardiovascular diseases are a leading cause of mortality and pose a significant burden on healthcare systems worldwide. Despite remarkable progress in medical research, the development of effective cardiovascular drugs has been hindered by high failure rates and escalating costs. One contributing factor is the limited availability of mature cardiomyocytes (CMs) for accurate disease modeling and drug screening. Human induced pluripotent stem cell‐derived CMs offer a promising source of CMs; however, their immature phenotype presents challenges in translational applications. This review focuses on the road to achieving mature CMs by summarizing the major differences between immature and mature CMs, discussing the importance of adult‐like CMs for drug discovery, highlighting the limitations of current strategies, and exploring potential solutions using electro‐mechano active polymer‐based scaffolds based on conductive polymers. However, critical considerations such as the trade‐off between three‐dimensional systems and nutrient exchange, biocompatibility, degradation, cell adhesion, longevity, and integration into wider systems must be carefully evaluated. Continued advancements in these areas will contribute to a better understanding of cardiac diseases, improved drug discovery, and the development of personalized treatment strategies for patients with cardiovascular disorders.This article is protected by copyright. All rights reserved